Sham ranibizumab

DRUG2 trials

Sponsors

Novartis, Novartis Pharmaceuticals

Conditions

Diabetic Macular EdemaPathological Myopia

Phase 3

Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema

CompletedNCT00989989

NovartisDiabetic Macular Edema

Start: 2009-09-30End: 2011-08-31Updated: 2012-10-18

Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

CompletedNCT01217944

Novartis PharmaceuticalsPathological Myopia

Start: 2010-10-31End: 2012-08-31Updated: 2014-02-10

Related Papers

Ranibizumab in Diabetic Macular Oedema - A Benefit-risk Analysis of Ranibizumab 0.5 mg PRN Versus Laser Treatment.

2017-08-224 citations

Initiation of intravitreal aflibercept injection treatment in patients with diabetic macular edema: a review of VIVID-DME and VISTA-DME data.

2016-07-1128 citations